The Basic Science Core (BSC;Core D) will enhance basic and laboratory-based HIV/AIDS research by CFAR members, by providing access to cutting-edge instrumentation and technologies, and the necessary support, education and training to enable efficient use of these resources. The services provided by Core D will create added value by addressing resource gaps on campus, and by providing CFAR SWG members with access to enhanced services for chemical biology and drug development. Over the funding period of our D-CFAR, Core D has been highly successful in leveraging new equipment valued at over $2M (a 18:1 ROI), and in helping to create a new strategic partnership between UR and Temple University's Moulder Center for Drug Discovery Research. The Core has also developed a highly proactive, user-oriented, approach that has allowed it to serve almost half (42%) of the total DCFAR membership. Building on this solid foundation, five Aims are proposed.
Aim 1 will provide cutting-edge tools and standardized reagents for virology, immunology, and molecular biology of HIV-1, including recombinant Tat for our CNS Reservoirs/Aging SWG, and a new FPLC resource for our RNA Biology SWG.
Aim 2 will provide expertise and resources for chemical and structural biology, including full-service medicinal chemistry resources and a new pilot program with the Moulder Center, of value to both SWGs.
Aim 3 will provide access to next-generation flow cytometry, including imaging- and mass- cytometry. Finally, Aim 4 will provide training and education to promote the use of new tools, and Aim 5 will integrate Core D services with other Cores and institutional resources - thus ensuring comprehensive attention to investigator needs.
; The Basic Science Core (BSC;Core D) will enhance basic and laboratory-based HIV/AIDS research by CFAR members, by providing access to cutting-edge instrumentation and technologies, and the necessary support, education and training to enable efficient use of these resources.
|Zhang, Gang; Guo, Dongwei; Dash, Prasanta K et al. (2016) The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine 12:109-22|
|Piepenbrink, Michael S; Samuel, Memorie; Zheng, Bo et al. (2016) Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users. PLoS One 11:e0158641|
|Fedor, Theresa M; Kohler, Hans-Peter; McMahon, James M (2016) Changing attitudes and beliefs towards a woman's right to protect against HIV risk in Malawi. Cult Health Sex 18:435-52|
|Nishimura, Christopher; Polesskaya, Oksana; Dewhurst, Stephen et al. (2016) Quantification of Cerebral Vascular Architecture using Two-photon Microscopy in a Mouse Model of HIV-induced Neuroinflammation. J Vis Exp :e53582|
|Makita-Chingombe, Faithful; Kutscher, Hilliard L; DiTursi, Sara L et al. (2016) Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations. J Drug Deliv 2016:3810175|
|Blanchard, Catlyn; Brooks, Lauren; Ebsworth-Mojica, Katherine et al. (2016) Zinc Pyrithione Improves the Antibacterial Activity of Silver Sulfadiazine Ointment. mSphere 1:|
|Liu, Bilan; Qiu, Xing; Zhu, Tong et al. (2016) Spatial regression analysis of serial DTI for subject-specific longitudinal changes of neurodegenerative disease. Neuroimage Clin 11:291-301|
|Yang, Hongmei; Baker, Steven F; GonzÃ¡lez, Mario E et al. (2016) An improved method for estimating antibody titers in microneutralization assay using green fluorescent protein. J Biopharm Stat 26:409-20|
|Blanchard, Catlyn; Brooks, Lauren; Beckley, Andrew et al. (2016) Neomycin Sulfate Improves the Antimicrobial Activity of Mupirocin-Based Antibacterial Ointments. Antimicrob Agents Chemother 60:862-72|
|Jones, Letitia D; Jackson, Joseph W; Maggirwar, Sanjay B (2016) Modeling HIV-1 Induced Neuroinflammation in Mice: Role of Platelets in Mediating Blood-Brain Barrier Dysfunction. PLoS One 11:e0151702|
Showing the most recent 10 out of 128 publications